These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 32231703)

  • 21. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation.
    Lee SR; Choi EK; Kwon S; Han KD; Jung JH; Cha MJ; Oh S; Lip GYH
    Stroke; 2019 Aug; 50(8):2245-2249. PubMed ID: 31208303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct oral anticoagulant reversal: how, when and issues faced.
    Dzeshka MS; Pastori D; Lip GYH
    Expert Rev Hematol; 2017 Nov; 10(11):1005-1022. PubMed ID: 28901221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurement and reversal of the direct oral anticoagulants.
    Samuelson BT; Cuker A
    Blood Rev; 2017 Jan; 31(1):77-84. PubMed ID: 27625113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
    Eikelboom JW; Quinlan DJ; Hirsh J; Connolly SJ; Weitz JI
    JAMA Cardiol; 2017 May; 2(5):566-574. PubMed ID: 28355459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of Severe Bleeding in Patients Treated With Oral Anticoagulants: Proceedings Monograph From the Emergency Medicine Cardiac Research and Education Group-International Multidisciplinary Severe Bleeding Consensus Panel October 20, 2018.
    Gibler WB; Racadio JM; Hirsch AL; Roat TW
    Crit Pathw Cardiol; 2019 Sep; 18(3):143-166. PubMed ID: 31348075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Review on the Use of Reversal Agents of Direct Oral Anticogulant Drugs in Case of Gastrointestinal Bleeding.
    Ojetti V; Saviano A; Brigida M; Saviano L; Migneco A; Franceschi F
    Rev Recent Clin Trials; 2020; 15(4):309-320. PubMed ID: 32579506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of direct oral anticoagulants: a practical approach.
    Shih AW; Crowther MA
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):612-619. PubMed ID: 27913536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs).
    Gelosa P; Castiglioni L; Tenconi M; Baldessin L; Racagni G; Corsini A; Bellosta S
    Pharmacol Res; 2018 Sep; 135():60-79. PubMed ID: 30040996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of new oral anticoagulants in orthopaedics: an update of recent evidence.
    Papadopoulos DV; Kostas-Agnantis I; Gkiatas I; Tsantes AG; Ziara P; Korompilias AV
    Eur J Orthop Surg Traumatol; 2017 Jul; 27(5):573-582. PubMed ID: 28314985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants.
    Eikelboom JW; Kozek-Langenecker S; Exadaktylos A; Batorova A; Boda Z; Christory F; Gornik I; Kėkštas G; Kher A; Komadina R; Koval O; Mitic G; Novikova T; Pazvanska E; Ratobilska S; Sütt J; Winder A; Zateyshchikov D
    Br J Anaesth; 2018 Apr; 120(4):645-656. PubMed ID: 29576106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What Surgeons Should Know About Non-Vitamin K Oral Anticoagulants: A Review.
    Verma A; Ha ACT; Rutka JT; Verma S
    JAMA Surg; 2018 Jun; 153(6):577-585. PubMed ID: 29710221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New Insights into Nonvitamin K Antagonist Oral Anticoagulants' Reversal of Intracerebral Hemorrhage.
    Yasaka M
    Front Neurol Neurosci; 2015; 37():93-106. PubMed ID: 26588018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations.
    De Caterina R; Ageno W; Agnelli G; Chan NC; Diener HC; Hylek E; Raskob GE; Siegal DM; Verheugt FWA; Lip GYH; Weitz JI
    Thromb Haemost; 2019 Jan; 119(1):14-38. PubMed ID: 30597497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring and reversal of direct oral anticoagulants.
    Cuker A; Siegal D
    Hematology Am Soc Hematol Educ Program; 2015; 2015():117-24. PubMed ID: 26637710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence.
    Bracey A; Shatila W; Wilson J
    Ther Adv Cardiovasc Dis; 2018 Dec; 12(12):361-380. PubMed ID: 30270775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current status of oral anticoagulant reversal strategies: a review.
    Rawal A; Ardeshna D; Minhas S; Cave B; Ibeguogu U; Khouzam R
    Ann Transl Med; 2019 Sep; 7(17):411. PubMed ID: 31660310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct oral anticoagulants: a review on the current role and scope of reversal agents.
    Chaudhary R; Sharma T; Garg J; Sukhi A; Bliden K; Tantry U; Turagam M; Lakkireddy D; Gurbel P
    J Thromb Thrombolysis; 2020 Feb; 49(2):271-286. PubMed ID: 31512202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Skjøth F; Larsen TB; Rasmussen LH; Lip GY
    Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.